Navigation Links
Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
Date:6/22/2013

of nocturnal hypoglycemia (0.9 vs. 1.2 events/30 days). Hypoglycemia rates in LY2605541-treated patients were statistically higher during some daytime and evenings, which resulted in the need to reduce mealtime insulin doses during the study.[1]

"This additional analysis showed that patients treated with LY2605541 achieved effective glycemic control with less mealtime insulin, which is exciting because it further supports our hypothesis that LY2605541 has a novel mechanism of action," said David Kendall, M.D., distinguished medical fellow, Lilly Diabetes. "We are encouraged by the potential benefits LY2605541 may offer patients and are pleased that our data support its ongoing development."

LY2605541, which was discovered and developed in Lilly Research Laboratories, is currently in Phase III clinical trials, and is among several diabetes molecules in Lilly's late-stage pipeline. The company has approximately a dozen potential new medicines for the treatment of diabetes and its related conditions, encompassing both large and small molecules, and targeting a variety of mechanisms.

About the Phase II Study Analysis
The Phase II, randomized, open-label, 2x2 crossover study evaluated whether LY2605541 was non-inferior (similar) to insulin glargine in reducing daily mean blood glucose in adults with type 1 diabetes. One hundred thirty-seven patients received LY2605541 or insulin glargine once daily, plus mealtime insulin, for eight weeks; they then switched treatments for an additional eight weeks. Daily mean blood glucose values were obtained from self-monitoring of blood glucose (SMBG) profiles (blood glucose readings before and two hours after a meal, at bedtime and at 3 a.m.) collected on three separate days the week prior to each visit. Hypoglycemic events (i.e., blood glucose less than 70 mg/dL) were captured throughout the study. All insulins were adjusted to optimize glycemic control.

The add
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
5. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
8. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
9. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
10. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
11. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, ... (CTMC), and Integrated Clinical Trial Services, LLC (ICTS), ... for clinical trials announce that they have formed ... Services (i-CTMS). i-CTMS will provide a broad range ... biotechnology and medical device companies. i-CTMS ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ) ... Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor ... http://photos.prnewswire.com/prnh/20130307/600769 ... a lot of progress in the past few ... accepted in high-reliability environments, and are even starting ...
Breaking Medicine Technology:ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... Ikaria Holdings, Inc. today announced that it has been ... by the New Jersey Business & Industry Association (NJBIA), ... Ikaria earned the award based on criteria including ... creation of new jobs. , "We are delighted that ...
... 21 PharmaNet Development Group, Inc., a leading provider ... and medical device companies, today announced its participation at ... place at the World Trade Center in Rotterdam, The ... the conference, top management will discuss some of the ...
Cached Medicine Technology:Ikaria Receives Award for Excellence by New Jersey Business & Industry Association 2PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam 2
(Date:12/17/2014)... 2014 Dr. Myo Nwe is the co-author ... of the Future” and co-founder of the Ace Medical Weight ... Nwe takes a broad look at the industry of weight ... scientific scrutiny. On film and in television shows, however, she ... the social aspects and played for basic laughs, which she ...
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 A group ... Center for Longevity, today, in reaction to a recent statement ... science of brain training and derogated the efficacy of all ... they agreed with the parts of the center’s statement critical ... believed the center had also overstated its case, in a ...
(Date:12/17/2014)... 17, 2014 Project Veritas is releasing ... videos of MIT economist and Obamacare architect Jonathan Gruber ... O’Keefe conducted the interview, which is being distributed on ... was intentional mislabeling in the Affordable Care Act in ... A two-hundred-and-fifty billion dollar per year tax grab. , ...
(Date:12/17/2014)... Dec. 16, 2014 (HealthDay News) -- Poor students get more ... a new study finds. But, the opposite is true ... having fruits and vegetables at school may give a healthy ... But, no matter what the family income level, students all ... the study found. The study was published recently in ...
(Date:12/17/2014)... Kathleen Doheny HealthDay Reporter ... loss is rampant in America, and work commitment is a ... No. 1 sleep killer," said Dr. Mathias Basner, an assistant ... of Pennsylvania Perelman School of Medicine. A time-use survey ... that work is the main activity exchanged for sleep. Short ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3
... may soon recommed patients who have undergone bowel surgery to ... found by Santa Barbara Cottage Hospital researchers that chewing gum ... This may in turn result in early discharge from the ... in the latest issue of Archives of Surgery journal. ...
... been a spurt of fungal infections in contact lens wearers ... against the seven reported last month. //This takes the overall ... suffered corneal infections and the Singapore National Eye Centre (SNEC) ... used Bausch and Lomb's (B&L) ReNu with MoistureLoc solution and ...
... Ramdev signed agreements with the Jharkhand government to set up ... plants.// ,The memorandums of understanding were signed in the ... ,Announcing government aid of Rs.10 million for the planned hospital, ... a herbal state that can benefit the common people of ...
... bizarre to you readers but if new research is to be ... // ,This revelation comes from American scientists who found that ... is by way of an increase the number of nerve connections ... ,The Yale University is credited with the study and ...
... of anabolic steroids, more specifically anabolic androgen steroid (AAS) ... sebaceous glands. Sebaceous glands present in the skin // ... of the body surface. ,Anabolic steroids are ... to treat unwanted weight loss in patients with HIV. ...
... of destruction caused by the Indian Ocean tsunami, the Katrina ... tsunami was responsible for the annihilation of 300,000 lives with ... tsunami arrived, it appeared as if the tourists were tsunami’s ... perhaps the only ones to sport a video camera at ...
Cached Medicine News:
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: